KRAS and colorectal carcinoma: There were no statistically significant differences caused by the combined effect of BRAF and KRAS on CRC stages I, III, or IV, regarding 3-year OS (p = 0.71, 0.9, and 0.91, respectively) or DFS rates (p = 0.85, 0.44, and 0.61, respectively).